Stage III Endometrial Cancer: Analysis of Prognostic Factors and Failure Patterns after Adjuvant Chemotherapy

Aoki, Yoichi; Kase, Hiroaki; Watanabe, Minoru; Sato, Takaaki; Kurata, Hiroyuki; Tanaka, Kenichi

doi:10.1006/gyno.2001.6321

Cited by 51 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be addressed by the addition of radiation [8]. Others have reported high pelvic recurrence rates when chemotherapy is used as the sole adjuvant therapy for patients with advanced endometrial cancer [16]. Combination of radiotherapy and chemotherapy is a potential strategy that may be used to improve both local and distant disease control.…”

Section: Discussionmentioning

confidence: 98%

Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been declared that studies before 1990 just reported peritoneal washings to be significantly associated with prognosis (Mazurka et al, 1988;Turner et al, 1989). Studies after 1990 indicate different results (Aoki et al, 2001;Hirai et al, 2001;Obermair et al, 2001). As a result, peritoneal washing cytology was dropped from FIGO 2009 staging criteria for endometrial carcinoma.…”

Section: Endometrial Carcinomasmentioning

confidence: 99%

Prognostic Value of Peritoneal Washing Cytology in Gynecologic Malignancies: a Controversial Issue

Binesh

Akhavan²,

Behniafard³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…At a median follow-up time of 37 months, the 3-year survival rate of patients with extrauterine disease was 46%. Aoki et al [19] reported on 61 patients with stage III disease, including 24 patients with nodal metastases who were treated by five cycles of CAP after surgery. The 5-year survival rate for patients with stage IIIC disease was 68%.…”

Section: Other Treatmentsmentioning

confidence: 99%

Endometrial cancer: Treatment of nodal metastases

McMeekin

Tillmanns

2003

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Surgical staging has changed the method by which patients with endometrial cancer are managed. Before the routine use of lymph node dissection, patients were presumed to have nodal disease based on imaging studies, palpation, and biopsy. The move to a surgically based staging system in 1988 created a new subgroup of patients who had documented nodal disease. The risk of nodal involvement is related primarily to tumor grade and depth of myometrial invasion. Although patients with nodal disease are uncommon, treatment of these patients poses multiple challenges. It is our belief that unless nodes are surgically assessed, the clinician will not know whether the nodes are involved. A thorough lymphadenectomy with removal of nodal tissue from multiple pelvic sites and from bilateral para-aortic regions is recommended for most patients with endometrial cancer. Identification of positive nodes allows appropriate postoperative therapies to be used, and data support that nodal dissection may be therapeutic and prognostic. Patients with positive nodes should receive radiation therapy directed to the nodal distribution, with patients having involved para-aortic nodes receiving an extended field. Whole abdominal radiation has been used, especially in patients with adnexal disease or positive cytology. The role of whole abdominal radiation remains in question. The most promising treatment option is combination therapy with sequential radiation and chemotherapy. Active chemotherapy agents in endometrial cancer are doxorubicin, cisplatin, and paclitaxel.

show abstract

Stage III Endometrial Cancer: Analysis of Prognostic Factors and Failure Patterns after Adjuvant Chemotherapy

Cited by 51 publications

References 25 publications

Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer

Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer

Prognostic Value of Peritoneal Washing Cytology in Gynecologic Malignancies: a Controversial Issue

Endometrial cancer: Treatment of nodal metastases

Contact Info

Product

Resources

About